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EXPERT OPINION
Abstract: Venlafaxine XR is a novel, dual acting SNRI antidepressant, which inhibits both 
serotonin and norepinephrine reuptake. Controlled trials have demonstrated the efﬁ  cacy and 
safety of venlafaxine in the treatment of panic disorder. Generally well tolerated, with side-
effects that usually abate with continued treatment, venlafaxine is an important option to the 
SSRIs for the treatment of patients with panic disorder.
Keywords: anxiety disorders, panic disorder, antidepressant therapy, remission, venlafaxine, 
selective serotonin norepinephrine reuptake inhibitor
Introduction
Anxiety disorders are persistent, cause substantial impairment, and are extremely com-
mon, with lifetime prevalence estimates of over 25% (Kessler et al 1994). As well, 
it has been reported that the anxiety disorders exert a substantial burden, not only in 
terms of direct costs of medication and psychotherapy, but also indirect costs associ-
ated with impaired functioning in social, educational, and employment aspects of life 
(Greenberg et al 1999). The annual cost of anxiety disorders in the United States was 
estimated to be US $42.3 billion in 1990, and US $65 billion in 1994 (Greenberg et al 
1999; Dupont et al 2002). Unfortunately, anxiety disorders are frequently only treated 
to a response rate often deﬁ  ned as a ≥50% improvement on the speciﬁ  c disease speciﬁ  c 
objective rating scale (Ballenger 2001). This can leave patients with substantial mor-
bidity, and in fact, many patients after having what was deﬁ  ned as a “good response” 
to monotherapy, would still fulﬁ  ll entry criteria for many trials. Clearly, this is disap-
pointing as it has become quite clear that remission should be the ultimate treatment 
goal in chronic anxiety disorders (Guidelines for the treatment 2000; Ballenger 2001). 
Remission in anxiety disorders has been deﬁ  ned as a patient who is symptom free and 
has a restoration of normal functioning, who is in fact indistinguishable from a person 
who had never suffered an anxiety disorder (Table 1) (Ballenger 2001).
Panic disorder is characterized by recurrent unexpected panic attacks followed by 
one month or more of persistent worry about having additional panic attacks (anticipatory 
anxiety), worry about the implications of the attack, or signiﬁ  cant changes in behavior 
(in relation to the panic attack). In addition, in order for the diagnosis of panic disorder 
to be made, the panic attacks cannot be due to the psychological effects of a substance 
or a medical condition, nor should the triggers for the panic attacks be better accounted 
for by anxiety episodes occurring in conjunction with other psychiatric disorders such 
as social phobia, post-traumatic stress disorder or depression (APA 1994).
The criterion for a panic attack according to DSM IV-TR requires 4 of the 13 
symptoms. In addition, many sufferers may experience “Limited Symptom Attacks,” 
which are similar to panic attacks but occur with fewer than 4 symptoms. These Limited 
Symptom Attacks, may still be quite disabling and often appear in combination with 
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the more severe four symptom panic attacks (Klerman et al 
1991). In addition, because panic attacks are usually followed 
by  the development of anticipatory anxiety (fear of having 
future panic attacks which often leads to agoraphobia and 
avoidance), a better estimate of severity may be how much 
the illness prevents the patient from doing. This is further 
complicated by the comorbidities that often develop in asso-
ciation with panic disorder (including depression, substance 
abuse, agoraphobia), as well as the signiﬁ  cant social and 
occupational impairment.
Agoraphobia, which often accompanies panic disorder 
refers, to a patient’s “fear or avoidance of situations from 
which escape might be difﬁ  cult or embarrassing or from 
which help may not be readily available” (APA 1994). 
The frequency of attacks is often used as an indicator of 
the severity of panic disorder, but this may be misleading, 
as the number of panic attacks or limited symptom attacks 
may be decreased by avoidance of situations in which one 
feels anxious, thus providing a false indicator of improved 
mental health. Thus, as stated by Shear and Maser (1994), 
the assessment of the severity of panic disorder should not 
only include panic attack (and limited symptom attack) fre-
quency and severity but also severity of phobic avoidance 
and interference with level of function. As a result, most 
recent studies in the treatment of panic disorder have used 
The Panic Disorder Severity Scale (PDSS) developed by 
Shear et al (1997), which is a validated instrument to assess 
all of these speciﬁ  c aspects of panic disorder. 
Drug therapy in panic disorder 
Thus the goals of pharmacotherapy are not only to reduce the 
severity and frequency of panic attacks and limited symptom 
attacks, but also to decrease the avoidance, fearful anticipa-
tion, and cognitive distortions associated with the diagnosis. 
The effectiveness of several types of medications is clearly 
established, but there remains no guarantee that a certain 
medication will work in a speciﬁ  c case. Thus the develop-
ment of more treatment effective options is imperative. As 
well, the potential presence of common co-existing condi-
tions as well as the presence of on-board medications must 
be included in the initial evaluation, because the presence of 
these comorbid conditions may affect the outcome of treat-
ment of the speciﬁ  c treatment for panic disorder (Lydiard 
and Brawman-Mintzer 1997). 
In terms of outcome for studies, the deﬁ  nition of remis-
sion has been widely debated. Most recently, Feighner (1999) 
proposed the deﬁ  nition given in Table 1. 
Inevitably, the question arises as to what is the ﬁ  rst-line 
pharmacotherapeutic treatment for panic disorder. While 
much evidence has pointed to the use of SSRIs (selective 
serotonin reuptake inhibitors) as the ﬁ  rst choice in treat-
ment, signiﬁ  cant research also points to the efﬁ  cacy of the 
other antidepressants including the tricyclic/heterocyclic 
antidepressants (TCAD) and monoamine oxidase inhibitors 
(MAOI). Nevertheless, these agents are unable to match 
the SSRIs in relationship to issues of tolerability, safety in 
overdose, and their broader range of established efﬁ  cacy 
in commonly co-occurring conditions. Thus the American 
Psychiatric Association Practice Guidelines for panic disorder 
(Pollack 1999) and the Canadian guidelines suggest that SSRIs 
(Canadian Anxiety Disorders Treatment Guidelines Initia-
tive 2006) remain ﬁ  rst-line treatment. Even though evidence 
clearly supports the role for SSRIs as ﬁ  rst-line treatments for 
panic disorder, the response and remission rates suggest a 
need for more options in managing panic disorder. Studies 
examining the effectiveness of the SSRIs in panic disorder 
are listed in Table 2. 
Venlafaxine
Venlafaxine hydrochloride (Effexor®; Wyeth-Ayerst 
Co., PA, USA), a structurally novel phenylethylamine 
(C17H27NO2 hydrochloride) antidepressant, was ﬁ  rst intro-
duced in 1994 for the treatment of major depression (Muth 
et al 1986) in its immediate-release form. This medication 
is now available as an extended-release (XR) formulation 
(Effexor® XR, Wyeth-Ayerst Co., PA, USA), which is 
indicated for the treatment of major depressive disorder, 
generalized anxiety disorder, panic disorder, and social 
anxiety disorder (social phobia) (Wyeth Laboratories 2003). 
Venlafaxine itself undergoes extensive metabolism in the 
liver to N-desmethyl-venlafaxine, N,O didesmethyl-venla-
faxine, and a few other minor metabolites, but primarily to 
O-desmethyl-venlafaxine (ODV), which is equiactive and 
equipotent to venlafaxine.
Table 1 Proposed objective remission target in panic disorder 
(Feighner 1999)
  Essentially free of panic attacks, no or mild 
 agoraphobic  avoidance
Panic Disorder  Or
  Panic Disorder Severity Scale (PDSS) ≤3
  with no individual item 
 score  >1Neuropsychiatric Disease and Treatment 2007:3(1) 61
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Mechanisms of action 
The mechanism of antidepressant action of venlafaxine in 
humans is believed to be associated with its potentiation 
of neurotransmitter activity in the central nervous system 
(CNS). Venlafaxine and its active metabolite, ODV, are 
potent inhibitors of neuronal serotonin and norepinephrine 
reuptake and weak inhibitors of dopamine reuptake (Muth 
et al 1986; Wyeth Laboratories 2003). This weak interaction 
with dopamine receptors may have clinical applicability at 
very high doses (Feighner 1999). Speciﬁ  cally, venlafaxine 
will inhibit reuptake at the noradrenergic reuptake site in 
the prefrontal cortex (which takes up both noradrenaline 
in noradrenergic synapses and dopamine in dopaminergic 
synapses), which speciﬁ  cally will increase concentration of 
not only noradrenaline but also dopamine in the prefrontal 
cortex (Moron et al 2002).
However, venlafaxine does not interact with muscarinic 
cholinergic, H1-histaminergic, or α1-adrenergic receptors in 
vitro, which are thought to be associated with the various 
anticholinergic, sedative, and cardiovascular effects seen 
with some other psychotropic drugs ( Feighner 1999; Wyeth 
laboratories 2003). It also possesses no monoamine oxidase 
inhibitory activity (Wyeth Laboratories 2003). Venlafaxine 
rapidly decreases central beta-adrenergic responsiveness, 
which is seen only after chronic administration of other 
antidepressants and may correlate with the onset of clinical 
activity. It exhibits a dose response, and at higher doses the 
adrenergic effects of the drug are increased (Feighner 1999).
Pharmacokinetic proﬁ  le
Steady-state plasma concentrations of venlafaxine and its 
active metabolite, ODV, are obtained within 3 days of oral 
multiple-dose administration and exhibit linear kinetics over 
the dose range 75–450 mg/day. The mean ± SD steady state 
plasma clearance of venlafaxine and ODV is 1.3 ± 0.6 and 
0.4 ± 0.2 L/h/kg, respectively; apparent elimination half-
life is 5 ± 2 and 11 ± 2 hours, respectively. The apparent 
(steady-state) volume of distribution is 7.5 ± 3.7 and 5.7 
± 1.8 L/kg, respectively. The degree of plasma protein 
binding is minimal (27% and 30%, respectively) (Wyeth 
Laboratories 2003). 
Approximately 92% of a single oral dose of venlafaxine is 
absorbed, with a bioavailability of 45%. The bioavailability 
of venlafaxine or ODV is not affected by food or time of 
administration (Wyeth Laboratories 2003). When equal daily 
doses of venlafaxine are administered, as immediate-release 
or the extended-release, exposure to both venlafaxine and 
ODV is similar and the ﬂ  uctuation in plasma concentrations 
is slightly lower with the venlafaxine XR capsule. Venlafaxine 
XR formulation provides a slower rate of absorption, but the 
same extent of absorption compared with the immediate-
release tablet. 
Venlafaxine is metabolized in the liver, primarily by 
CYP2D6, but any differences between CYP2D6 and exten-
sive metabolizers are not expected to be clinically important 
(Wyeth Laboratories 2003). 
Excretion of venlafaxine and ODV is primarily through 
the kidneys, and the approximate elimination half-life is 5 
hours for venlafaxine and 11 hours for ODV. Within 48 
hours, 87% of a single dose was recovered in the urine as 
unchanged venlafaxine (5%), unconjugated ODV (29%), 
conjugated ODV (26%), or other minor inactive metabolites 
(27%). There is no difference in the elimination half-life 
between venlafaxine and venlafaxine XR (Wyeth Labora-
tories 2003). 
Venlafaxine in panic disorder 
A number of concerns have been raised as to whether 
there is a role for venlafaxine in the treatment of panic 
disorder, related to its role in noradrenergic reuptake 
blockade. Because of its known efﬁ  cacy in the other anxiety 
disorders, studies have been initiated with venlafaxine in 
panic disorder. 
Table 2 List of studies examining the effectiveness of SSRIs in 
panic disorder 
SSRI  Daily dosage   Studies
 range
Fluvoxamine  (150–300 mg)  Black et al (1993) 
    Hoehn-Saric et al (1993)
Paroxetine  (40–60 mg)  Ballenger et al (1998)
    Lydiard et al (1998)
    Oehrberg et al (1995)
Sertraline  (50–200 mg)  Londborg et al (1998)
    Pohl et al (1998)
    Pollack et al (1998)
    Rapaport et al (1998)
    Pollack et al (2000)
    Rapaport et al (2001)
    Pollack et al (2002)
Citalopram  (20–40 mg)  Wade et al (1997)
    Lepola et al (1998)
    Leionen et al (2000)
Fluoxetine  (10–20 mg)  Michelson et al (1998)
    Michelson et al (1999)
    Michelson et al (2001)Neuropsychiatric Disease and Treatment 2007:3(1) 62
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Liebowitz and colleagues (2004) undertook a placebo-
controlled, ﬂ  exible-dose trial of venlafaxine XR in patients 
suffering from panic disorder with or without agoraphobia. 
In this trial, 323 subjects meeting study criteria (including 
baseline CGI-S [Clinical Global Impression-Severity Scale] 
≥4, ≥8 full symptom panic attacks in the 4-weeks preceding 
admission to the study and ≥4 full symptom panic attacks in 
the 17 days preceding entry into the study) were randomly 
enrolled in a 10-week trial of venlafaxine (ﬂ  exible dose 
range 75–225 mg daily) or placebo, with a 2-week taper 
period. The primary outcome measure was the number of 
patients who were free from full symptom panic attacks (≥4 
symptoms) as measured on the PAAS (Panic and Anxiety 
Anticipatory Scale), at the last and ﬁ  nal visit on therapy 
(FOT) evaluation. Secondary outcome measures included 
the change in the total PDSS (Panic Disorder Severity 
Scale), and the response rate as measured on the Clinical 
Global Impression-Improvement at a score of 1 (very much 
improved) or 2 (much improved). As well, Liebowitz and 
colleagues (2004) assessed changes in panic frequency (as 
measured on the PAAS, Remission Rate (CGI-Severity of 1 
and panic free), Phobia Scales (fear and avoidance factors), 
change from baseline in percentage of time that patients 
experience anticipatory anxiety, as well as changes reported 
quality of life (Q-LES-Q; Quality of Life Enjoyment and 
Satisfaction Questionnaire), and disability (on the SDS; 
Sheehan Disability Scale). After the 10-week trial, Liebowitz 
et al (2004) reported that with a mean daily dose ranging 
from 125.6 to 194.1 mg, signiﬁ  cant differences were noted 
in total PDSS change (p ≤ 0.05) beginning at week 4, with 
signiﬁ  cantly more venlafaxine XR patients reaching response 
at week 4 and 10 than those in the placebo group. While not 
statistically signiﬁ  cant, trends towards signiﬁ  cance were 
observed in terms of remission rate (p = 0.067), percentage 
of panic-free patients (p = 0.056), and the median change 
in panic frequency from baseline (p = 0.058). Liebowitz 
and colleagues (2004) also reported signiﬁ  cant reductions 
in the phobia scale (fear and avoidance factors) but not the 
percentage of time patients suffered with anticipatory anxiety 
(see Table 3). 
Bradwejn and colleagues (2005) reported on a second 
10-week trial (with a 2-week taper period) of venlafaxine 
(ﬂ  exible dose range 75–225 mg daily) or placebo in patients 
suffering with panic disorder with or without agoraphobia. In 
this trial, 323 subjects meeting study criteria (including baseline 
CGI-S [Clinical Global Impression-Severity Scale] ≥4, ≥8 full 
symptom panic attacks in the 4-weeks preceding admission to 
the study and ≥4 full symptom panic attacks in the 17 days 
preceding entry into the study) were randomly enrolled in 
the 10-week trial of venlafaxine or placebo. The primary 
outcome measure was the percentage of patients free from 
full symptom panic attacks (≥4 symptoms) as measured on 
the PAAS (Panic and Anxiety Anticipatory Scale), at the 
FOT evaluation. Secondary outcome measures included the 
median change from baseline in the panic attack frequency, 
as measured on the PAAS, change in the total PDSS (Panic 
Disorder Severity Scale), and the response rate as measured 
on the Clinical Global Impression-Improvement at a score of 
1 (very much improved) or 2 (much improved), Remission 
Rate (CGI-Severity of 1 and panic free), Phobia Scales (fear 
and avoidance factors), change from baseline in percentage of 
time that patients experience anticipatory anxiety, as well as 
changes in reported quality of life (Q-LES-Q; Quality of Life 
Enjoyment and Satisfaction Questionnaire), and disability (on 
the SDS; Sheehan Disability Scale). After the 10-week trial, 
Bradwejn et al (2005) reported that a mean daily dose ranging 
from 115 to 163 mg resulted in signiﬁ  cant differences in 
reduction of panic attack frequency from baseline, compared 
with the placebo-treated group (p ≤ 0.05). Interestingly, while 
there was a signiﬁ  cant difference in percentage of patients 
who were panic free on venlafaxine XR at weeks 4 and 8, 
no difference was found at the FOT evaluation. This may 
have been related to the difference in baseline panic attacks 
in the venlafaxine XR treatment group (with a signiﬁ  cantly 
larger baseline rate in panic attacks in the venlafaxine group). 
However, Bradwejn et al (2005) reported signiﬁ  cant differ-
ences in response and remission rates (p ≤ 0.05), with almost 
70% of the patients on venlafaxine XR reaching response as 
measured on the CGI. As well, signiﬁ  cant improvement in 
the Q-LES-Q and three of the four domains of the SDI was 
also noted (Table 3). 
In another short-term trial, Pollack et al (2005) reported 
on a randomized, placebo-controlled, 12-week, multi-center 
clinical trial of paroxetine at a dose of 40 mg daily, venlafaxine 
XR at a dose of 75 mg daily, venlafaxine XR at a dose of 225 
mg daily, and placebo in patients suffering from DSM-IV 
diagnosed panic disorder with or without agoraphobia. Six 
hundred and twenty-one subjects completed the trial. The 
primary outcome measure was the number of subjects free 
from full symptom panic attacks (≤4 symptom panic attacks). 
Secondary outcome measures included the total PDSS (Panic 
Disorder Severity Scale), the response rate (endpoint CGI-I 
of 1 or 2), the remission rate (endpoint CGI-S of 1 or 2 and 
panic free), change from baseline in panic attack frequency Neuropsychiatric Disease and Treatment 2007:3(1) 63
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as noted on the PAAS (Panic and Anxiety Anticipatory 
Scale), change in the percentage of time subjects experience 
anticipatory anxiety, Phobia Scale (fear and Avoidance 
factors), and the Q-LES-Q (Quality of Life Enjoyment and 
Satisfaction Questionnaire). Pollack et al (2005) reported that 
all three treatment groups showed signiﬁ  cant improvement 
in the primary and secondary outcome measures in rela-
tion to the placebo-treated group, but that in particular, the 
group treated with 225 mg venlafaxine XR per day showed 
improvement in the percentage of patients who were panic 
free (p ≤ 0.023) and a greater total score improvement in the 
total PDSS compared with the group receiving paroxetine 
at a dose of 40 mg daily (p ≤ 0.033). This difference, while 
signiﬁ  cant, may represent an unfair choice of dosing for 
paroxetine, suggesting that a higher dose of paroxetine may 
have been more effective. As well, signiﬁ  cant improvements 
with the venlafaxine XR- and paroxetine-treated groups 
showed a 75% response rate and roughly a 50% remission 
rate at completion of the study (Table 3).
In a comparison of quality of life and functionality 
with venlafaxine XR and paroxetine and placebo, Khandker 
et al (2005) reported speciﬁ  cally on a variety of secondary 
outcome measures of functional impairment including the 
Sheehan Disability Scale and the Quality of Life Enjoyment 
and Satisfaction Questionnaire (Q-LES-Q). Impairment 
levels were assessed at baseline, and treatment-related 
improvement measured at FOT evaluation and at 12 weeks. 
Khandker et al (2005) reported that the group taking 225 
mg/day of venlafaxine XR showed signiﬁ  cant differences 
from pre-treatment baseline measures in nine of the ten 
domains of the Q-LES-Q (p ≤ 0.005), the only domain 
not showing a signiﬁ  cant difference being the School and 
Coursework domain. This differed from the group taking 
75 mg/day of venlafaxine XR, who showed signiﬁ  cant 
changes from pre-treatment baseline measures in eight of 
the ten domains (p ≤ 0.05), with the only domains not showing 
difference from baseline being the School and Coursework 
domain and the Household Duties domain. Interestingly, the 
group receiving paroxetine at a dose of 40 mg/day showed 
signiﬁ  cant differences from pre-treatment baseline measures 
in all ten domains of the Q-LES-Q.
As for the results with the Sheehan Disability Scale, 
Khandker et al (2005) reported that signiﬁ  cant changes were 
noted in all four domains of the SDS (work; social life and 
leisure activities; family life and home responsibilities; and 
work and social disability) with venlafaxine XR at 75 mg/day 
Table 3 Double-blind trials evaluating venlafaxine XR in patients with panic disorder
Duration,  Treatments,   % Completers  % Panic free  % Responders   Remission rate 
patients, daily  dose    on  PAAS   1based upon   based upon CGI = 1
baseline score         CGI = 1 or 2  and being panic
        free + CGI = 1
Panic disorder 
Liebowitz et al  Venlafaxine   100/155 = 64.5%  79/155 = 51.0%  1108/155 = 69.7%  57/155 = 36.8%
2004 (ﬂ  exible dose 
10-wk taper  75–225 mg)
period ≤2 weeks,  Mean dose
n = 310  (125.6–194.1 mg/day)
  Placebo  112/155 = 72.3%  63/155 = 40.6%  190/155 = 58.1%  42/155 = 27.1%
Pollack et al 2005  Venlafaxine XR 
  75 mg od  136/160 = 85.0%   101/160 = 63.1%  183.2 70/160  =  43.75%
  150 mg od  137/166 = 82.5%  112/166 = 67.5%  188.8 74/166  =  45%
 Paroxetine 
  40 mg od  126/161 = 75.9%  88/161 = 54.7%  183.8 73/161  =  45%
  Placebo  119/162 = 73.5%  75/162 = 46.3%  62.3  41/162 = 25%
Bradwejn et al 2005  Venlafaxine   137/177 = 77.4%  88/177 = 48.71%  1109/177 = 61.58%  57/177 = 32.20%
 ( ﬂ  exible dose 
 (75–225  mg)
 Mean  dose 
  (115–163 mg daily)
  Placebo  137/178 = 77.0%  88/178 = 49.44  193/178 = 52.24  41/178 = 23%Neuropsychiatric Disease and Treatment 2007:3(1) 64
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(p ≤ 0.01), venlafaxine XR at 225 mg/day (p ≤ 0.001), and 
paroxetine at 40 mg/day (p ≤ 0.05).
Ferguson et al (2005) recently undertook a multicenter, 
randomized, placebo-controlled, parallel group study of 313 
patients, 18 years or older, suffering with panic disorder, who 
were enrolled initially in an open-label trial of venlafaxine 
XR, with those who met criteria for “responder” (≤1 panic 
attack per week in the ﬁ  nal 2 weeks prior to the end of the 
open-label phase and a CGI score of 1 or 2) being randomized 
to a 12-week placebo-controlled, parallel group comparison 
study. Outcome measures included the primary outcome mea-
sure of time to relapse, with secondary outcome measures of 
the PAAS (Panic and Anxiety Anticipatory Scale) including 
the percentage of patients who are panic-free and the PAAS 
panic frequency and the PDSS (Panic Disorder Severity 
Scale), CGI-S, Phobia Scale Fear Factor, Phobia Scale 
Avoidance Factor, Overall Phobia Scale, Hamilton Anxiety 
Scale, Montgomery Asberg Rating Scale (MADRS), Sheehan 
Disability Rating Scale (SDS), Quality of Life Enjoyment and 
Satisfaction Questionnaire (Q-LES-Q), Resource Utilization 
in Panic Disorder (RUPD). Ferguson et al (2005) reported 
that the 92 subjects randomized to the venlafaxine XR group 
showed a signiﬁ  cantly lower relapse rate (22.5%) compared 
with the relapse rate (50%) in the 90 subjects randomized to 
the placebo group (p < 0.001). Statistical differences were 
noted between the two groups in the secondary outcome mea-
sures including number of panic attacks, PDSS anticipatory, 
psychic, somatic fear and avoidance subscales and the CGI-S, 
the SDS subscales of work, social life and leisure activities, 
family life and home responsibilities, global work and social 
disability scores (p < 0.001), and all but one of the Q-LES-Q 
subscales (school and course work). 
Mallick et al (2004) reported on a recent pooled analysis 
of two short-term randomized placebo-controlled studies of 
venlafaxine XR (75 mg, 150 mg, and ﬂ  exible dose), one of which 
included the paroxetine comparison group (Pollack et al 2005) 
during 10–12 weeks of treatment for panic disorder, and on a 
pooled analysis of four randomized, double-blind, placebo-
controlled studies (two of which were also paroxetine con-
trolled). Mallick et al (2003) reported that at baseline, score 
of the physical health activities subscale of the Q-LES-Q was 
2.8 (the lowest of the Q-LES-Q subscales) and that changes in 
the subscale were substantially changed in both the venlafaxine 
groups compared with the placebo group. 
In summary, while it may have been suggested that 
venlafaxine as an SNRI would not be an effective treatment 
for panic disorder, there are clear data showing that it is at 
least as effective as the SSRI paroxetine, As such, further 
and larger comparison trial and/or meta-analyses should be 
undertaken to examine whether there is any clear advantage 
of venlafaxine over the SSRIs in panic disorder.
Safety and tolerability
In large trials in patients with social anxiety disorder (SAD) 
or generalized anxiety disorder (GAD), the most common 
treatment-related adverse events were nausea, insomnia, 
anorexia, asthenia, dizziness, and sexual dysfunction 
(Greenberg et al 1999; Gelenberg et al 2000; Mallick et al 
2002; Wyeth Laboratories 2003). Side-effects are similar to 
those seen in patients with depression and generally subside 
with continued treatment (Wyeth laboratories 2003, Mallick 
et al 2002). 
Approximately 17%–18% of patients with SAD or GAD 
withdrew from venlafaxine treatment because of adverse 
events, compared with 5%–12% of placebo-treated patients 
(Wyeth Laboratories 2003). The most common adverse event 
leading to discontinuation and considered to be drug-related 
was nausea at 4%–8%. Other events leading to discontinu-
ation in 1%–3% of patients were asthenia, headache, dry 
mouth, dizziness, insomnia, somnolence, nervousness, 
sweating, and impotence in men.
In studies on panic disorder, the drop out rate because 
of adverse events on the venlafaxine XR was 9%–10% in 
the venlafaxine XR groups compared with 2%–5% in the 
placebo group vs 7% in the paroxetine group. No signiﬁ  cant 
difference was noted in the groups in any of the three short-
term studies. 
While electrocardiograph changes have been noted in 
some trials, generally they have been minor and of no clinical 
signiﬁ  cance (Katz et al 2002). However, venlafaxine treat-
ment has been associated with sustained increases in blood 
pressure in some patients (0.5%–1.4%). Pooled analysis 
of 5 trials including 1839 patients with GAD treated with 
venlafaxine for 8 weeks reported a non-signiﬁ  cant 0.6 mmHg 
decrease in supine diastolic blood pressure in older patients 
(Katz et al 2002). Venlafaxine-treated patients in GAD and 
SAD studies experienced signiﬁ  cantly higher mean changes 
in heart rate than placebo-treated patients (a mean increase 
of 3–5 beats per minute for venlafaxine and no change for 
placebo) (Wyeth Laboratories 2003). However, analysis of 
older patients with GAD showed no signiﬁ  cant changes in 
heart rate (Smith et al 2002). 
In patients with renal impairment or cirrhosis of the liver, 
the clearance of venlafaxine is decreased, and the elimination Neuropsychiatric Disease and Treatment 2007:3(1) 65
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half-life is prolonged (Wyeth Laboratories 2003). This suggests 
that extra care must be taken to ensure the safety of venlafaxine 
in this population.
Signiﬁ  cant weight gain can be an unwanted effect of many 
antidepressant drugs. However, venlafaxine XR has little effect 
on body weight, with anorexia and weight loss reported in a 
small percentage of patients (Wyeth Laboratories 2003).
Rare but important adverse events with venlafaxine have 
been reported, including hyponatremia and/or the syndrome 
of inappropriate antidiuretic hormone secretion (SIADH) and 
mydriasis (Mallick and Gao 2003). There have been reports 
of abnormal bleeding (ecchymosis) associated with venlafax-
ine treatment, but in these rare cases no causal relationship 
was ever established. Clinically relevant increases in serum 
cholesterol were recorded in 5.3% of venlafaxine patients 
treated for at least 3 months in placebo-controlled trials.
Antidepressant therapy has also been reported to cause 
a switch to mania or hypomania in patients with bipolar 
disorder. Since anxiety disorders are frequently comorbid 
with bipolar disorder, this is an important consideration. 
In anxiety trials, there have been no reports of venlafaxine 
XR-treated patients experiencing mania or hypomania and 
only a 0.5% incidence in major depressive disorder trials 
(Mallick and Gao 2003). Nonetheless, venlafaxine should 
be used with caution in patients with a history of mania 
(Mallick and Gao 2003).
Drug interactions
The primary metabolizing enzymes for venlafaxine are 
CYP2D6 and CYP3A4 and the potential for interaction exists 
with drugs that produce simultaneous inhibition of these 
two enzyme systems. Venlafaxine is either a weak inhibitor 
or does not inhibit other CYP enzymes (Wyeth Laboratories 
2003). Venlafaxine appears to have a low potential to inhibit 
the metabolism of substrates for CYP2D6 such as imipramine, 
desipramine, and risperidone, and is unlikely to be involved in 
a pharmacokinetic interaction (Amchin et al 1999; Albers et al 
2000; Wyeth Laboratories 2003). Minor but clinically relevant 
interactions have been reported between venlafaxine and 
lithium, diazepam, and haloperidol (Troy et al 1996; Benazzi 
1997; Mekler and Woggon 1997; Kudo and Ishizaki 1999; 
Mallick and Gao 2003). Cimetidine should be co-administered 
with caution in patients with compromised hepatic metabolic 
function (Troy et al 1998; Mallick and Gao 2003). In addition, 
venlafaxine should be used cautiously in patients receiving 
indinavir, as signiﬁ  cant decreases in serum levels of indinavir 
can result (Levin et al 2001; Mallick and Gao 2003). 
As with most antidepressant drugs, a potential interaction 
with MAOIs does exist with venlafaxine XR, and serious adverse 
reactions have been reported (Brubacher et al 1996; Gitlin 1997; 
Hodgman et al 1997; Mallick and Gao 2003). Venlafaxine XR 
should not be used be used in combination with an MAOI, or 
within at least 14 days of discontinuing treatment with an MAOI. 
Based on the half-life of venlafaxine, at least 7 days should be 
allowed after stopping venlafaxine before starting an MAOI. 
Conclusion
Venlafaxine is a useful pharmacological choice for the treatment 
of anxiety disorders, including SAD, GAD, post traumatic stress 
disorder (PTSD), OCD, and most recently panic disorder. Its 
demonstrated short-term and long-term efﬁ  cacy makes it an 
obvious choice as a ﬁ  rst-line treatment in panic disorder. Anxiety 
disorders frequently occur with major depressive disorder, and 
other psychiatric and somatic conditions. With its demonstrated 
efﬁ  cacy in major depressive disorder and low risk of serious 
adverse events, venlafaxine can be used conﬁ  dently in patients 
with panic disorder and its depression and anxiety comorbidities. 
The beneﬁ  ts of venlafaxine in patients with eating disorders and 
somatic pain syndromes further suggest its potential utility in 
patients with multiple comorbid conditions. 
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